Provided by Tiger Fintech (Singapore) Pte. Ltd.

PTC Therapeutics

49.55
-0.4000-0.80%
Post-market: 49.550.00000.00%16:47 EDT
Volume:806.72K
Turnover:39.91M
Market Cap:3.91B
PE:-10.48
High:50.39
Open:50.03
Low:48.86
Close:49.95
Loading ...

PTC Therapeutics Price Target Maintained With a $65.00/Share by RBC Capital

Dow Jones
·
22 Apr

PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy?

Zacks
·
17 Apr

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results

PR Newswire
·
17 Apr

Top Executive Sells Hundreds of PTC Therapeutics Shares!

TIPRANKS
·
05 Apr

RBC Lifts Price Target on PTC Therapeutics to $65 From $64, Keeps Outperform Rating

MT Newswires Live
·
03 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Eli Lilly, Roku among others added to Wells Fargo's tactical ideas list

Investing.com
·
01 Apr

PTC Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
31 Mar

PTC Therapeutics price target lowered to $75 from $78 at JPMorgan

TIPRANKS
·
31 Mar

U.S. RESEARCH ROUNDUP- Braze, Home Bancshares, Union Pacific

Reuters
·
31 Mar

BUZZ-U.S. STOCKS ON THE MOVE-GameStop, Oxford Industries, Wolfspeed

Reuters
·
29 Mar

BUZZ-PTC Therapeutics falls as EC to not renew market authorization for muscle disorder drug

Reuters
·
28 Mar

PTC Therapeutics says EC will not renew market authorization for muscle disorder drug

Reuters
·
28 Mar

PTC Therapeutics (PTCT) Gets a Hold from TD Cowen

TIPRANKS
·
28 Mar

PTC Therapeutics Loses EU Authorization for Translarna in Duchenne Muscular Dystrophy

MT Newswires Live
·
28 Mar

PTC Therapeutics Shares Fall After EU Drops Translarna Authorization

Dow Jones
·
28 Mar

PTC Therapeutics Shares Down 8.2% Premarket as Co's Muscle Disorder Therapy to Be Removed From European Markets

THOMSON REUTERS
·
28 Mar

PTC Therapeutics says European Commission will remove muscle disorder drug

Reuters
·
28 Mar

BRIEF-PTC Therapeutics Provides Regulatory Update On Translarna™ (Ataluren) In Europe

Reuters
·
28 Mar

PTC Therapeutics : Disappointed That After Prolonged Period of Review European Commission Has Decided to Adopt Chmp Negative Opinion on Translarna

THOMSON REUTERS
·
28 Mar